Matinas BioPharma
MTNB
51 hedge funds and large institutions have $9.31M invested in Matinas BioPharma in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
4% more funds holding
Funds holding: 49 → 51 (+2)
0.36% less ownership
Funds ownership: 12.26% → 11.9% (-0.36%)
46% less capital inflows, than outflows
Capital inflows: $431K | Capital outflows: $799K
54% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$261K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$72K |
| 3 |
Virtu Financial
New York
|
+$42K |
| 4 |
BlackRock
New York
|
+$18.5K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$9.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neville Rodie & Shaw
New York
|
-$278K |
| 2 |
Bridgeway Capital Management
Houston,
Texas
|
-$166K |
| 3 |
Sargent Investment Group
Bethesda,
Maryland
|
-$153K |
| 4 |
Millennium Management
New York
|
-$90.6K |
| 5 |
Jane Street
New York
|
-$27.2K |
MTNB Hedge Fund Activity: Q2 2023 in Review
51 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2023, worth a combined $9.31M — down 26% from $12.6M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new MTNB positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 13 trimmed.
The largest buyer was Wells Fargo, adding an estimated $261K. The largest seller was Neville Rodie & Shaw, cutting an estimated $278K.
- 51 institutional investors held Matinas BioPharma (MTNB) as of Q2 2023, up from 49 in Q1 2023.
- Funds reported $9.31M of Matinas BioPharma stock for Q2 2023, down 26% quarter-over-quarter.
- 5 funds opened new Matinas BioPharma positions in Q2 2023 and 3 closed out, a net change of +2 holders.
- The largest Matinas BioPharma buyer in Q2 2023 was Wells Fargo, an estimated $261K added.
- The largest Matinas BioPharma seller in Q2 2023 was Neville Rodie & Shaw, an estimated $278K sold.
Based on aggregated 13F filings for Q2 2023.